Pantherna Therapeutics was founded in 2017 and is a privately held biopharmaceutical company focused on developing first-in-class therapies for vascular diseases. The company’s proprietary technology platform utilizes advanced nanoparticle delivery systems to transport and express therapeutic messenger RNA (mRNA) specifically within the endothelium, the inner lining of blood vessels. By combining mRNA-based medicine with targeted delivery technologies, Pantherna Therapeutics aims to address unmet medical needs in cardiovascular and vascular disorders through innovative treatments that promote vascular repair, regeneration, and improved patient outcomes.